Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Dermata Therapeutics Inc(DRMA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DRMA
11/12/2026: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Dermata Therapeutics is a small-cap biotechnology company that has pivoted into a direct-to-consumer skincare brand under its 'Tome' label. The company’s core strength lies in its proprietary Spongilla-based technology, which it now leverages for consumer-facing skin renewal products. Its investment story centers on the potential to scale its DTC channel and achieve commercial success with its Tome brand. However, the company faces significant risks, including limited financial resources, intense competition from established global skincare brands, and execution challenges following its recent business model shift. Dermata is most suitable for speculative investors who are comfortable with high volatility and the risks associated with an early-stage consumer product launch.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company's early-stage commercial status and significant capital requirements make it a high-risk proposition rather than a proven growth stock. |
| Momentum investor | Mixed fit | Price swings associated with clinical results and corporate pivots provide short-term opportunities, but the stock lacks sustained upward momentum. |
| Value investor | Weak fit | The company is not currently profitable and carries high execution and valuation risk. |
| Dividend investor | Weak fit | Dermata pays no dividends and is focused on capital preservation and growth. |
| Low-risk investor | Weak fit | High volatility and the potential for 'going concern' risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to news regarding its commercial execution and capital raises. |
| Valuation risk | High | The company's market cap is small and depends entirely on the future success of its Tome skincare brand. |
| Competition risk (Skin/Beauty incumbents) | High | Dermata must compete with deep-pocketed, established brands for consumer mindshare and shelf space. |
| Business quality | Medium | The shift from drug development to a consumer brand is an unproven transition for the current management team. |
| Dividend income | Low / none | There is no income generation from this stock. |
| Execution risk | High | Scaling a direct-to-consumer brand requires sustained marketing and operational success that the company has not yet demonstrated. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.54M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 5.9M shares | Beta 0.58 | 52 Weeks Range 0.60 - 3.16 | Updated Date 11/12/2026 |
52 Weeks Range 0.60 - 3.16 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.39 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -28.51% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Direct-to-Consumer (DTC) | Online sales of the Tome Foundational Treatment via the company's website. | Revenue is earned by selling skincare kits directly to consumers, with a focus on building recurring subscription revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1.01M | Price to Sales(TTM) 47.79 |
Enterprise Value -1.01M | Price to Sales(TTM) 47.79 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 4.96M | Shares Floating 3.29M |
Shares Outstanding 4.96M | Shares Floating 3.29M | ||
Percent Insiders 22.32 | Percent Institutions 12.19 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.